DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Has $59.21 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 57.0% in the fourth quarter, Holdings Channel reports. The fund owned 301,303 shares of the medical research company’s stock after selling 399,586 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in IQVIA were worth $59,209,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the 4th quarter valued at $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at $44,000. Zions Bancorporation N.A. grew its position in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter worth about $60,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $153.39 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a fifty day moving average of $164.60 and a 200-day moving average of $189.07. The firm has a market capitalization of $27.04 billion, a P/E ratio of 20.45, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.54 earnings per share. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. Robert W. Baird reduced their price target on IQVIA from $195.00 to $161.00 and set a “neutral” rating on the stock in a report on Wednesday. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Truist Financial cut their price target on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. Citigroup decreased their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a report on Wednesday. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $231.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.